J A Frank1, J-F Pittet, C Wray, M A Matthay. 1. Cardiovascular Research Institute, University of California, San Francisco VA Medical Center, 4150 Clement St, Box 111D, San Francisco, CA 94121, USA. james.frank@ucsf.edu
Abstract
BACKGROUND: Clinical studies have shown that injurious mechanical ventilation is associated with increased airspace and plasma levels of interleukin-1beta (IL-1beta); however, the potential therapeutic value of IL-1 inhibition in acute lung injury has not been thoroughly investigated. A study was undertaken to determine if IL-1 signalling is a necessary early event in the pathogenesis of experimental ventilator-induced lung injury. METHODS: Mice deficient in IL-1 receptor type 1 (IL1R1) and rats treated with IL-1 receptor antagonist (IL-1Ra) were mechanically ventilated with high tidal volume (30 ml/kg) and the effect of IL-1 signalling blockade on the severity of lung injury was determined. RESULTS: Permeability, as measured by radiolabelled albumin flux, was significantly lower in IL1R1 null mice than in wild-type mice during injurious ventilation (p<0.05). IL-1Ra significantly decreased protein permeability and pulmonary oedema in rats during injurious ventilation and also decreased airspace and plasma levels of the chemokine CXCL1 and airspace neutrophils. IL-1Ra decreased expression of NOS2 and ICAM-1 mRNA in whole lung. Bronchoalveolar lavage fluid levels of RTI40, a marker of type I cell injury, were 2.5 times lower following IL-1Ra treatment (p<0.05). In isolated type II pneumocytes, IL-1beta reduced electrical resistance and increased transepithelial permeability. CONCLUSIONS: IL-1 contributes to alveolar barrier dysfunction in VILI by promoting lung neutrophil recruitment and by increasing epithelial injury and permeability. Because preserved alveolar barrier function is associated with better outcomes in patients with acute lung injury, these data support further testing of IL-1Ra for the treatment of acute lung injury.
BACKGROUND: Clinical studies have shown that injurious mechanical ventilation is associated with increased airspace and plasma levels of interleukin-1beta (IL-1beta); however, the potential therapeutic value of IL-1 inhibition in acute lung injury has not been thoroughly investigated. A study was undertaken to determine if IL-1 signalling is a necessary early event in the pathogenesis of experimental ventilator-induced lung injury. METHODS:Mice deficient in IL-1 receptor type 1 (IL1R1) and rats treated with IL-1 receptor antagonist (IL-1Ra) were mechanically ventilated with high tidal volume (30 ml/kg) and the effect of IL-1 signalling blockade on the severity of lung injury was determined. RESULTS: Permeability, as measured by radiolabelled albumin flux, was significantly lower in IL1R1 null mice than in wild-type mice during injurious ventilation (p<0.05). IL-1Ra significantly decreased protein permeability and pulmonary oedema in rats during injurious ventilation and also decreased airspace and plasma levels of the chemokine CXCL1 and airspace neutrophils. IL-1Ra decreased expression of NOS2 and ICAM-1 mRNA in whole lung. Bronchoalveolar lavage fluid levels of RTI40, a marker of type I cell injury, were 2.5 times lower following IL-1Ra treatment (p<0.05). In isolated type II pneumocytes, IL-1beta reduced electrical resistance and increased transepithelial permeability. CONCLUSIONS:IL-1 contributes to alveolar barrier dysfunction in VILI by promoting lung neutrophil recruitment and by increasing epithelial injury and permeability. Because preserved alveolar barrier function is associated with better outcomes in patients with acute lung injury, these data support further testing of IL-1Ra for the treatment of acute lung injury.
Authors: Anne B Lipke; Gustavo Matute-Bello; Raquel Herrero; Venus A Wong; Stephen M Mongovin; Thomas R Martin Journal: Am J Physiol Lung Cell Mol Physiol Date: 2011-04-22 Impact factor: 5.464
Authors: Kristin M Hudock; Yuhong Liu; Junjie Mei; Roberta C Marino; Jason E Hale; Ning Dai; G Scott Worthen Journal: Am J Respir Cell Mol Biol Date: 2012-05-16 Impact factor: 6.914
Authors: John H Frankel; Devin M Boe; Joslyn M Albright; Eileen B O'Halloran; Stewart R Carter; Christopher S Davis; Luis Ramirez; Ellen L Burnham; Richard L Gamelli; Majid Afshar; Elizabeth J Kovacs Journal: Exp Gerontol Date: 2017-10-26 Impact factor: 4.032
Authors: Kieran Brune; James Frank; Andreas Schwingshackl; James Finigan; Venkataramana K Sidhaye Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-01-30 Impact factor: 5.464
Authors: Charlie Wray; Ying Mao; Jue Pan; Anita Chandrasena; Frank Piasta; James A Frank Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-05-15 Impact factor: 5.464
Authors: Holger C Müller; Katharina Hellwig; Simone Rosseau; Thomas Tschernig; Andreas Schmiedl; Birgitt Gutbier; Bernd Schmeck; Stefan Hippenstiel; Harm Peters; Lars Morawietz; Norbert Suttorp; Martin Witzenrath Journal: Crit Care Date: 2010-07-30 Impact factor: 9.097
Authors: E Cantu; D J Lederer; K Meyer; K Milewski; Y Suzuki; R J Shah; J M Diamond; N J Meyer; J W Tobias; D A Baldwin; V M Van Deerlin; K M Olthoff; A Shaked; J D Christie Journal: Am J Transplant Date: 2013-05-24 Impact factor: 8.086